Review
Version 1
Preserved in Portico This version is not peer-reviewed
Relative Effectiveness of Cell-Cultured versus Egg-Based Seasonal Influenza Vaccines in Preventing Influenza-Related Outcomes in Subjects 18 Years Old or Older: A Systematic Review and Meta-Analysis
Version 1
: Received: 6 November 2021 / Approved: 8 November 2021 / Online: 8 November 2021 (12:14:08 CET)
Version 2 : Received: 6 December 2021 / Approved: 20 December 2021 / Online: 20 December 2021 (11:00:26 CET)
Version 2 : Received: 6 December 2021 / Approved: 20 December 2021 / Online: 20 December 2021 (11:00:26 CET)
A peer-reviewed article of this Preprint also exists.
Puig-Barberà, J.; Tamames-Gómez, S.; Plans-Rubio, P.; Eiros-Bouza, J.M. Relative Effectiveness of Cell-Cultured versus Egg-Based Seasonal Influenza Vaccines in Preventing Influenza-Related Outcomes in Subjects 18 Years Old or Older: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 818. Puig-Barberà, J.; Tamames-Gómez, S.; Plans-Rubio, P.; Eiros-Bouza, J.M. Relative Effectiveness of Cell-Cultured versus Egg-Based Seasonal Influenza Vaccines in Preventing Influenza-Related Outcomes in Subjects 18 Years Old or Older: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 818.
Journal reference: Int. J. Environ. Res. Public Health 2022, 19, 818
DOI: 10.3390/ijerph19020818
Abstract
Avian mutations in vaccine strains obtained from embryonated eggs could impair vaccine effec-tiveness. We performed a systematic review and meta-analysis of the adjusted relative vaccine effectiveness (arVE) of seed cell-cultured influenza vaccines (ccIV) compared to egg-based influ-enza vaccines (eIV) in preventing laboratory-confirmed influenza related outcomes (IRO) or IRO by clinical codes, in subjects 18 and over. We completed the literature search in January 2021; ap-plied exclusion criteria, evaluated risk of bias of the evidence, and performed heterogeneity, pub-lication bias, qualitative, quantitative and sensitivity analyses. All estimates were computed us-ing a random approach. International Prospective Register of Systematic Reviews, CRD42021228290. We identified 12 publications that reported 26 adjusted arVE results. Five publications reported 13 laboratory confirmed arVE and seven reported 13 code-ascertained arVE. Nine publications with 22 results were at low risk of bias. Heterogeneity was explained by season and risk of bias. We found a significant 11% (8 to 14%) adjusted arVE favoring ccIV in preventing any IRO in the 2017-2018 influenza season. The arVE was 3% (-01 to 7%) in the 2018-2019 influenza season. We found moderate evidence of a significant advantage of the ccIV in preventing IRO, compared to eIV, in a well-matched A(H3N2) predominant season.
Keywords
adults; influenza; cell-cultured vaccine; egg-based vaccine; influenza vaccine; relative vaccine effectiveness; real word evidence; mutation; human / prevention & control*; comparative study
Subject
MEDICINE & PHARMACOLOGY, Other
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.
Leave a public commentSend a private comment to the author(s)
Commenter:
Commenter's Conflict of Interests: The corresponding author on behalf of the authors.